-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 MsMlZd/jX8XNS0Lfrh5CvH8HbejzMkedN6bOJNZphkK9169vMcmLE06cS21XODkX
 4HHCQm140jmBq8jaDssRvA==

<SEC-DOCUMENT>0001181431-10-008439.txt : 20100211
<SEC-HEADER>0001181431-10-008439.hdr.sgml : 20100211
<ACCEPTANCE-DATETIME>20100211152507
ACCESSION NUMBER:		0001181431-10-008439
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20100211
FILED AS OF DATE:		20100211
DATE AS OF CHANGE:		20100211

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			3SBio Inc.
		CENTRAL INDEX KEY:			0001383790
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33295
		FILM NUMBER:		10591571

	BUSINESS ADDRESS:	
		STREET 1:		NO.3 A1, ROAD 10 SHENYANG
		STREET 2:		ECONOMY & TECHNOLOGY DEVELOPMENT ZONE
		CITY:			SHENYANG
		STATE:			F4
		ZIP:			110027
		BUSINESS PHONE:		86-24-2581-1820

	MAIL ADDRESS:	
		STREET 1:		NO.3 A1, ROAD 10 SHENYANG
		STREET 2:		ECONOMY & TECHNOLOGY DEVELOPMENT ZONE
		CITY:			SHENYANG
		STATE:			F4
		ZIP:			110027
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>rrd265801.htm
<TEXT>

<html>
<head>
<title>Prepared By R.R. Donnelley - Form 6-K</title>
</head>
<body bgcolor="WHITE">


<hr align="left" color="#000000" noshade="noshade" size="3">

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="5"><b>SECURITIES AND EXCHANGE COMMISSION</b></font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="3"><b>Washington, DC 20549 </b></font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<hr color="#000000" noshade="noshade" size="1" width="17%">

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="5"><b>FORM 6-K</b></font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"></font>
</p>

<hr color="#000000" noshade="noshade" size="1" width="17%">

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="3"><b>REPORT OF FOREIGN PRIVATE ISSUER </b></font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="3"><b>Pursuant to Rule 13a-16 or 15d-16 of</b></font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="3"><b>the Securities Exchange Act of 1934 </b></font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2"><b>February 11, 2010</b></font>
</p>

	<p style="margin-top: 0px; margin-bottom: 0px;">
		<font size="1"> </font>
	</p>

	<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2"><b>Commission File Number: 000-33295</b>	</font>
	</p>

	<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
	</p>

	<hr color="#000000" noshade="noshade" size="1" width="17%">

	<p style="margin-top: 0px; margin-bottom: 0px;">
		<font size="1"> </font>
	</p>

	<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
		<font face="Times New Roman" size="6"><b>3SBio Inc.</b></font>
	</p>

	<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
		<font face="Times New Roman" size="1"><b>(Translation of registrant's name into English) </b></font>
	</p>

	<p style="margin-top: 0px; margin-bottom: 0px;">
		<font size="1"> </font>
	</p>

	<hr color="#000000" noshade="noshade" size="1" width="17%">

	<p style="margin-top: 0px; margin-bottom: 0px;">
		<font size="1"> </font>
	</p>
	<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
		<font face="Times New Roman" size="2">
			<b>
				No. 3 A1, Road 10<br>Shenyang Economy & Technology Development Zone<br>Shenyang 110027<br>People's Republic of China
			</b>
		</font>
	</p>

	<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
		<font face="Times New Roman" size="1"><b>(Address of principal executive offices) 	</b></font>
	</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<hr color="#000000" noshade="noshade" size="1" width="90%">

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">Indicate by check mark whether the registrant files or will </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">file annual reports under
cover of Form 20-F or Form 40-F. </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">
		Form 20-F <u><b>&nbsp;&nbsp;X&nbsp;&nbsp;</b></u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>
	</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1">&nbsp;</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font face="Times New Roman" size="2">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1):
		<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>
	</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font face="Times New Roman" size="2">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):
		<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>
	</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1">&nbsp;</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">Indicate by check mark whether the registrant by furnishing the </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">information contained
in this form is also thereby furnishing the </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">information to the Commission pursuant to Rule 12g3-2(b) under the </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">Securities Exchange Act of 1934.</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1"> </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">
		Yes
		<u>&nbsp;&nbsp;&nbsp;</u>
		&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
		No
		<u><b>&nbsp;&nbsp;X&nbsp;&nbsp;</b></u>
	</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1">&nbsp;</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">If "Yes" is marked, indicate below the file number assigned to the </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">registrant in connection with Rule 12g3-2(b): <u>82-</u>.
</font>
</p>

<p style="margin-top: 0px; margin-bottom: -6px;">
	<font size="1"> </font>
</p>

<hr align="left" color="#000000" noshade="noshade" size="3">

<hr align="center" color="#999999" size="3" width="100%">

<p style="margin-top: 0px; margin-bottom: -6px;">
 	<font face="Times New Roman" size="2">
 		&nbsp;
	</font>
</p>

<hr align="center" color="#999999" size="3" width="100%">

<p style="margin-top: 0px; margin-bottom: 0px;" align="center">
	<font face="Times New Roman" size="2">SIGNATURES </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1">&nbsp;</font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px; text-indent: 4%;">
	<font face="Times New Roman" size="2">Pursuant
	to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by
	the
	undersigned, thereunto duly authorized. </font>
</p>

<p style="margin-top: 0px; margin-bottom: 0px;">
	<font size="1">&nbsp;</font>
</p>
<table border="0" cellpadding="0" cellspacing="0" width="100%">

			<tr>
				<td valign="top">
					<p style="margin-left: 1em; text-indent: -1em;">
						<font face="Times New Roman" size="2">

						</font>
					</p>
				</td>
				<td colspan="3" valign="top">

						<font face="Times New Roman" size="2">
							3SBio Inc.
						</font>

				</td>
			</tr>

			<tr>
				<td valign="top">

						<font face="Times New Roman" size="2">
							Date : February 11, 2010
						</font>

				</td>
				<td valign="top">

						<font face="Times New Roman" size="2">
							By:
						</font>

				</td>

				<td valign="bottom">
					<font size="1"> </font>
				</td>
				<td valign="bottom">

						<font face="Times New Roman" size="2">
							<u>/s/ Dr. Jing Lou&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>
						</font>


				</td>
			</tr>
			<tr>
				<td valign="top">

						<font face="Times New Roman" size="2">

						</font>

				</td>
				<td valign="top">

						<font face="Times New Roman" size="2">
							Name:
						</font>

				</td>
				<td valign="bottom">
					<font size="1"> </font>
				</td>
				<td valign="bottom">

						<font face="Times New Roman" size="2">
							Dr. Jing Lou
						</font>

				</td>
			</tr>
			<tr>
				<td valign="top">

						<font face="Times New Roman" size="2">
							&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
						</font>

				</td>
				<td valign="top">

						<font face="Times New Roman" size="2">
							Title:
						</font>

				</td>

				<td valign="bottom">
					<font size="1"> </font>
				</td>
				<td valign="bottom">

						<font face="Times New Roman" size="2">
							Chief Executive Officer
						</font>

				</td>
			</tr>
			<tr>
				<td>
					&nbsp;
				</td>
			</tr>


		</table>


	<p Style='page-break-before:always'>
	<hr  Size="3" Width="100%" Align="center">
		<div Align="center"><font Face="times New Roman" Size="3" Color="#000000">
	<b>Exhibit Index </b></font>
	</div>

	<div><font Size="2">&nbsp;</font></div>

	<div Align="center">
	<table Cellspacing="0" Cellpadding="0" Width="100%" Border="0">
		<tr>
			<td Valign="top" Align="left">
		<div Align="left"><font Face="times New Roman" Size="2" Color="#000000">
		<b>Exhibit&nbsp;No.</b></font>
		</div>
			<hr Size="2" Noshade Width="48" Color="#000000">
			</td>
			<td Valign="top" Width="3%"><font Face="times New Roman" Size="2">&nbsp;&nbsp;</font></td>
			<td Valign="top" Width="100%" Align="left">
		<div><font Face="times New Roman" Size="2" Color="#000000">
		<b>Description</b></font>
		</div>
		<hr Size="2" Noshade Width="73" Align="left" Color="#000000">
			</td>
		</tr>


		<tr>
			<td Valign="top" Align="left">
		<div Align="left"><font Face="times New Roman" Size="1" Color="#000000">
		EX-99.1</font>
		</div>

			</td>
			<td Valign="top" Width="3%"><font Face="times New Roman" Size="2">&nbsp;&nbsp;</font></td>
			<td Valign="top" Width="100%" Align="left">
		<div><font Face="times New Roman" Size="2" Color="#000000">
		3SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil for Hyperphosphatemia</font>
		</div>
			</td>
		</tr>
		<tr>
			<td>
				&nbsp;
			</td>
		</tr>


		</table>


<BR><BR><BR>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>rrd265801_317.htm
<DESCRIPTION>3SBIO AND PANACOR BIOSCIENCE ENTER COLLABORATION AND LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE NEPHOXIL FOR HYPERPHOSPHATEMIA
<TEXT>
<HTML>
<HEAD>
<TITLE>FOR RELEASE NOVEMBER 12, 2009 5:00 pm Eastern Time</TITLE>
</HEAD>
<BODY>
<B><FONT SIZE=2><P ALIGN="JUSTIFY">FOR IMMEDIATE RELEASE </P>
</B></FONT><FONT SIZE=3><P ALIGN="JUSTIFY"></P><DIR>
<DIR>
<DIR>
<DIR>
</FONT><B><P ALIGN="CENTER">3SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil</B><FONT SIZE=2> </FONT><B>for Hyperphosphatemia</P>
<FONT SIZE=2><P>&nbsp;</P></DIR>
</DIR>
</DIR>
</DIR>
<P ALIGN="JUSTIFY">SHENYANG, CHINA</B> - February 8, 2010 - 3SBio Inc. (NASDAQ: SSRX) (&quot;3SBio&quot; or the &quot;Company&quot;), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced a collaboration and license agreement with Panacor Bioscience Ltd. to develop and commercialize its Nephoxil (*registered mark) pharmaceutical product for the treatment of hyperphosphatemia in China.  </P>
<P>Nephoxil (ferric citrate) is a differentiated, iron-based phosphate binder for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end stage renal disease (ESRD). Nephoxil is free of aluminum, lanthanum and calcium, and is not polymer-based. Due to the deterioration of kidney function, ESRD patients are unable to excrete phosphorus effectively even through frequent dialysis, and almost all patients require daily phosphate binder intake to control body phosphate levels. If not treated, hyperphosphatemia could lead to serious or fatal complications such as bone deformation (renal osteodystrophy), coronary calcification, heart disease, stroke and cardiovascular diseases which account for about half of the causes of death in the ESRD population. China represents a large and rapidly growing market with approximately 12 million Stage 3 and 4 chronic kidney disease (CKD) patients, and over 91,000 dialysis patients. </P>
<P>Nephoxil has completed Phase II clinical development programs, including a dose-ranging study, a high dose safety and tolerability study and an open-label extension study, with compelling clinical data. Nephoxil is developed globally and is entering Phase III clinical development in the United States, Japan and Taiwan. </P>
<P>Under the terms of the agreement, Panacor Bioscience will grant 3SBio exclusive commercialization rights to Nephoxil in China. Panacor Bioscience will receive an upfront equity investment of US$1 million and royalties on future product sales. 3SBio will be responsible for the cost of clinical development, registration, manufacturing and commercialization of Nephoxil in China. The agreement is subject to final approval by Taiwan's regulatory authorities, including the Investment Commission of the Taiwan Ministry of Economic Affairs. </P>
<P>&quot;We are excited to extend the franchise of Nephoxil into one of the most important markets for chronic kidney disease. We are very pleased to enter the relationship with 3SBio which has a proven track record of developing and marketing innovative pharmaceutical products in China,&quot; said Winston Town, Chief Executive Officer of Panacor Bioscience Ltd. </P>
<P>&quot;Given the limitation of existing phosphate binders in China, Nephoxil has the potential to improve the phosphate management of the growing number of CKD patients in China. We are optimistic about this new addition to our nephrology franchise and look forward to working with Panacor Bioscience as we start the SFDA approval process,&quot; said Dr. Jing Lou, Chief Executive Officer of 3SBio Inc. </P>
<B><P>About 3SBio Inc. <BR>
</B>3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at www.3sbio.com.</P>
<B><P>About Panacor Bioscience Ltd</P>
</B><P>Panacor Bioscience Ltd. is an emerging biopharmaceutical company focused on the development of innovative drug products that address unmet medical needs. Panacor possesses the expertise to develop its products for global registration and maximum commercial potential. Panacor has built a significant product pipeline that can enter into various stages of clinical development. Its lead product, Nephoxil, is entering Phase III clinical study and in global collaboration with multiple renowned pharmaceutical partners. </P>
<B><P ALIGN="JUSTIFY"></P>
<P>Safe Harbor Statement </P>
</B><I><P ALIGN="JUSTIFY">This press release contains statements of a forward-looking nature. These statements are made under the &quot;safe harbor&quot; provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by terminology such as &quot;will,&quot; &quot;expects,&quot; &quot;anticipates,&quot; &quot;future,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates&quot; and similar statements. The accuracy of these statements may be impacted by a number of business factors and uncertainties that could cause actual results to differ materially from those projected or anticipated, including factors related to: the risks related to 3SBio's ability to successfully initiate and complete clinical trials for Nephoxil in China, including the risk that clinical trials conducted by Panacor Bioscience for Nephoxil in the U.S., Taiwan or elsewhere could produce negative results which adversely affect 3SBio's trials and registr
ation; the risk that the Taiwan Ministry of Economic Affairs may not approve the collaboration and license agreement in a timely manner or at all; 3SBio's ability to commercialize and effectively market Nephoxil in China in a cost effective manner or at all; uncertainty as to hospital or patient demand for 3SBio's products; uncertainties regarding 3SBio's ability to obtain favorable insurance coverage and pricing for Nephoxil, if approved by the SFDA; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the P.R.C. government and changes in the healthcare insurance sector in the P.R.C.; fluctuations in general economic and business conditions in China; and other risks outlined in 3SBio's filings with the Securities and Exchange Commission. 3SBio does not undertake any obligation to update this forward-looking information, except as required under applicable law. </P>
</I><B><P>Investor Contacts</P>
</B><P>Bo Tan<BR>
Chief Financial Officer<BR>
3SBio Inc.<BR>
Tel: + 86 24 2581-1820<BR>
ir@3SBio.com</P>
<P>Tom Folinsbee<BR>
Director of Investor Relations<BR>
3SBio Inc. <BR>
Tel: + 852 8191-6991<BR>
ir@3SBio.com</P>
<P>&lt;END&gt;</P>
</FONT><FONT FACE="Lucida Sans" SIZE=2></FONT></BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
